Winchester, MA, United States of America

Ula Jurkunas

This inventor holds 1 USPTO granted patent. Top assignee: The Schepens Eye Research Institute, Inc.. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ula Jurkunas. Retrieved from https://idiyas.com/inventor/ula-jurkunas

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 1.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Ula Jurkunas and Research on Corneal Endothelium Disorders.

Introduction

Ula Jurkunas is an inventor associated with The Schepens Eye Research Institute, Inc., in Winchester, Massachusetts. Her patent work focuses on potential treatments for disorders affecting the corneal endothelium.

Latest Patents

Jurkunas is named on 1 patent, titled “Methods and Compositions for the Treatment of Corneal Endothelium Disorders.” The application describes methods and pharmaceutical compositions, including oral, parenteral, and topical ophthalmic formulations, for treating Fuchs endothelial corneal dystrophy (FECD).

Career Highlights

The disclosed invention addresses FECD by exploring treatment approaches and formulations intended for this corneal condition. Jurkunas’s listed institutional affiliation is The Schepens Eye Research Institute, Inc.

Collaborations

The patent application connects Jurkunas’s work with The Schepens Eye Research Institute, Inc. The provided information does not identify additional collaborators.

Conclusion

Ula Jurkunas’s patent activity centers on proposed methods and pharmaceutical compositions for treating FECD, reflecting a focus on innovation in corneal disease research.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…